Figure 4.
Targeted delivery of Dex-L-MVs into inflammatory lung in vivo. (A) The timeline of administration with Dex-L-MVs. (B) The weight change of mice (n = 6). (C) The fluorescence intensity of lipid-labeled macrophages in lung of mice over the time after intravenous injection with Dex-L-MVs. (D) the lung systemic toxicity of Dex-L-MVs. Scale bar = 100 μm. (E) The number of neutrophils and (F) the number of lymphocytes neutrophils per liter of peripheral blood (G–I) The secretion levels of inflammatory factors including IL-6 (G), TGF-β (H) and IL-1β (I) in mouse BALF on the 10th day. Data representative for three independent experiments, mean ± S.D. of at least four technical replicates per time point. #p < 0.05, ##p < 0.01, ###p < 0.001, vs. control group, *p < 0.05; **p < 0.01, vs. Model group.